Fig. 8

High concentrations of DCA activate YAP1 via ABL1. A mRNA expression levels of Parp1, Caspase3, and Abl1 in the ileum tissue of the mice (n = 5). B mRNA expression levels of PARP1 and ABL1 in human ileum tissue treated with 100 μM DCA for 24 h (n = 8 or 5). C Relative mRNA expression of ABL1, YAP1, CTGF, and CYR61 in human ex vivo tissue culture with DCA, or DCA combined with the ABL1 inhibitor Imatinib (n = 4). D Relative protein expressions of pYAP1, YAP1, pABL1, and ABL1 in HT-29 cells treated with or without DCA for 15 min. E Quantitative analysis of D (n = 6). F Relative mRNA expression of ABL1 and CYR61 in HT-29 cells treated with DCA alone, or with DCA combined with the ABL1 inhibitor Imatinib (n = 6). G The relative protein expressions of pYAP1 and YAP1 in HT-29 cells treated with DCA alone, or with DCA combined with the ABL1 inhibitor, Imatinib. H Quantitative analysis of G (n = 4). LFD, low-fat diet; HFD, high-fat diet; HFD + CHO, HFD + cholestyramine; DCA, deoxycholic acid. *P < 0.05, **P < 0.01, ***P < 0.001